Study population:
(1) Patients scheduled for defibrillation testing after (subcutaneous) implantable cardioverter defibrillator (ICD) implantation; 2) Patients undergoing transcatheter aortic valve implantation (TAVI) with intended rapid ventricular pacing; 3) Patients undergoing ventricular tachycardia ablation.